New combo therapy targets advanced prostate cancer in early trial
NCT ID NCT07389174
First seen Feb 05, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This early-phase study tests a new drug called LC-K76 combined with standard hormone therapy in 40 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and see if the drug helps lower PSA levels. Participants will take the drug for 24 weeks and be followed for another 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.